AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
tioconazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| systemic antifungal agents, miconazole derivatives | 2675 | 65899-73-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.30 | g | V |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 4.492 | Moderate | 0.78 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 1.030 | Moderate | 0.78 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 44.259 | 10^-6 cm/s | Moderate | 0.78 |
| dh-clint | Dog hepatocyte intrinsic clearance | 73.451 | uL/min/10^6 cells | Moderate | 0.78 |
| dppb | Dog plasma protein binding (% unbound) | 0.370 | % | Moderate | 0.78 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 1.170 | % | Moderate | 0.78 |
| herg | hERG pIC50 | 5.812 | pIC50 | Moderate | 0.78 |
| hh-clint | Human hepatocyte intrinsic clearance | 88.920 | uL/min/10^6 cells | Moderate | 0.78 |
| hlm-clint | Human liver microsomal intrinsic clearance | 234.423 | uL/min/mg protein | Moderate | 0.78 |
| hppb | Human plasma protein binding (% unbound) | 0.470 | % | Moderate | 0.78 |
| kinase-safety-class | ACVR2A,ACVR2B,AKT2,AKT3,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,GSK3B,ITK,JAK2,JAK3,MAP3K21,MAP3K7,MAPK12,MAPK7,MAPK9,MAPKAPK2,MET,NTRK2,PDK2,PDK4,PDPK1,PIK3CB,PIK3CG,PIM2,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK | 42 | |||
| kinase-selectivity-class | AKT3,AXL,BRAF,EIF2AK3,GRK2,PDK4,PIK3CB | 7 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.607 | Moderate | 0.78 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 138.676 | Moderate | 0.78 | |
| mppb | Mouse plasma protein binding (% unbound) | 0.440 | Moderate | 0.78 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.941 | Moderate | 0.78 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 1.850 | % | Moderate | 0.78 |
| rh-clint | Rat hepatocyte intrinsic clearance | 190.546 | uL/min/10^6 cells | Moderate | 0.78 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 6.900 | % | Moderate | 0.78 |
| rppb | Rat plasma protein binding (% unbound) | 0.390 | % | Moderate | 0.78 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 95.940 | uM | Moderate | 0.78 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 18, 1983 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D01AC07 | DERMATOLOGICALS ANTIFUNGALS FOR DERMATOLOGICAL USE ANTIFUNGALS FOR TOPICAL USE Imidazole and triazole derivatives |
| ATC | G01AF08 | GENITO URINARY SYSTEM AND SEX HORMONES GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS ANTIINFECTIVES AND ANTISEPTICS, EXCL. COMBINATIONS WITH CORTICOSTEROIDS Imidazole derivatives |
| FDA CS | M0002083 | Azoles |
| FDA EPC | N0000175487 | Azole Antifungal |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000935 | Antifungal Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D006727 | Hormone Antagonists |
| MeSH PA | D058888 | 14-alpha Demethylase Inhibitors |
| MeSH PA | D065088 | Steroid Synthesis Inhibitors |
| MeSH PA | D065606 | Metabolic Side Effects of Drugs and Substances |
| MeSH PA | D065607 | Cytochrome P-450 Enzyme Inhibitors |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
| CHEBI has role | CHEBI:77884 | EC 1.14.13.70 (sterol 14α-demethylase) inhibitor |
Related Drugs by ATC class:
D01AC Imidazole and triazole derivatives 20 drugs
G01AF Imidazole derivatives 16 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Candidal vulvovaginitis | indication | 72605008 | DOID:2272 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 6.49 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Steroid 17-alpha-hydroxylase/17,20 lyase | Enzyme | Ki | 6.30 | CHEMBL | |||||
| 7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase | Enzyme | INHIBITOR | Kd | 6.68 | IUPHAR | ||||
| Cysteine protease ATG4A | Enzyme | IC50 | 5.89 | CHEMBL | |||||
| Cysteine protease ATG4B | Enzyme | IC50 | 5.75 | CHEMBL | |||||
| Lanosterol 14-alpha demethylase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4020459 | VUID |
| N0000148215 | NUI |
| D00890 | KEGG_DRUG |
| 4020459 | VANDF |
| C0076705 | UMLSCUI |
| CHEBI:9604 | CHEBI |
| FJQ | PDB_CHEM_ID |
| CHEMBL1200438 | ChEMBL_ID |
| DB01007 | DRUGBANK_ID |
| C020527 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5482 | PUBCHEM_CID |
| 13859 | IUPHAR_LIGAND_ID |
| 4572 | INN_ID |
| S57Y5X1117 | UNII |
| 38298 | RXNORM |
| 5586 | MMSL |
| 002926 | NDDF |
| 332967005 | SNOMEDCT_US |
| 395909003 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| good sense tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 0113-0426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 0363-0426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| VAGISTAT | HUMAN OTC DRUG LABEL | 1 | 11509-0426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Up and up tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 11673-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| signature care tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 21130-060 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| TIOCONAZOLE 1 | HUMAN OTC DRUG LABEL | 1 | 21130-781 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Topcare Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 36800-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 37808-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Equaline Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 41163-032 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 41250-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| CareOne Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 41520-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| Equate tioconazole 1 day | HUMAN OTC DRUG LABEL | 1 | 49035-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| dg health tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 55910-731 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 59779-718 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| TIOCONAZOLEOintment 6.5% | HUMAN OTC DRUG LABEL | 1 | 63094-0426 | OINTMENT | 65 mg | VAGINAL | ANDA | 12 sections |
| Tioconazole1 Day | HUMAN OTC DRUG LABEL | 1 | 63736-410 | OINTMENT | 300 mg | TOPICAL | ANDA | 16 sections |
| MONISTAT TIOCONAZOLE 1 | HUMAN OTC DRUG LABEL | 1 | 63736-413 | OINTMENT | 6.50 g | TOPICAL | ANDA | 15 sections |
| Leader Tioconazole 1 | HUMAN OTC DRUG LABEL | 1 | 70000-0357 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| foster and thrive tioconazole | HUMAN OTC DRUG LABEL | 1 | 70677-1224 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |
| basic care tioconazole | HUMAN OTC DRUG LABEL | 1 | 72288-426 | OINTMENT | 6.50 g | VAGINAL | ANDA | 16 sections |